Response Genetics (RGDX) Reports Q4 Loss of $0.09/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Response Genetics, Inc. Announces Fourth Quarter and Year-End 2014 Financial Results
March 31, 2015 4:05 PM EDTLOS ANGELES, March 31, 2015 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the fourth quarter and full year ended December 31, 2014.
Total revenue for the fourth quarter ended December 31, 2014 was $4.1 million compared to $4.8 million for the quarter ended December 31, 2013. The Company's ResponseDX® revenue was $3.7 million compared to $3.2 million for the quarter ended December 31, 2013, an increase of 15.6%. The Company's pharmaceutical client revenue, which varies... More
Response Genetics, Inc. Announces Fourth Quarter and Year-End 2014 Financial Results
March 31, 2015 4:05 PM EDTLOS ANGELES, March 31, 2015 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the fourth quarter and full year ended December 31, 2014.
Total revenue for the fourth quarter ended December 31, 2014 was $4.1 million compared to $4.8 million for the quarter ended December 31, 2013. The Company's ResponseDX® revenue was $3.7 million compared to $3.2 million for the quarter ended December 31, 2013, an increase of 15.6%. The Company's pharmaceutical client revenue, which varies... More
